

Contributing Authors

Syed Rizwanuddin Ahmad MD MPH FISPE

Medical Epidemiologist, Division of Drug Risk Evaluation, Office of Surveillance and Epidemiology, Food and Drug Administration, CDER
Silver Spring, MD
Chapter 5

Nancy M Allen LaPointe PharmD

Associate Professor of Medicine, Department of Medicine, Duke University
Medical Center
Durham, NC
Chapter 30

Morten Andersen PhD

Senior Researcher, Research Unit of General Practice, University of Southern Denmark
Odense, Denmark
Chapter 8

Susan E Andrade ScD

Senior Research Associate, Assistant Professor of Medicine, Meyers Primary Care Institute, University of Massachusetts Medical School
Worcester, MA
Chapter 28

Elizabeth B Andrews PhD MPH

Vice President, Pharmacoepidemiology and Risk Management, RTI Health Solutions, RTI International
Research Triangle Park, NC
Chapters 23, 24

H Michael Arrighi PhD MSPH

Senior Director, Epidemiology, Elan Pharmaceuticals, Inc.
South San Francisco, CA
Chapter 35

Andrew Bate PhD

Research Manager, WHO Collaborating Centre for International Drug Monitoring
Uppsala, Sweden
Chapter 10

Vittorio Bertele' MD

Head, Regulatory Policies Laboratory, Mario Negri Institute for Pharmacological Research
Milano, Italy
Chapter 4

Steven Black MD

Research Scientist, Division of Research, Kaiser Permanente, Northern California
Co-Director, Kaiser Permanente Pediatric Vaccine Study Center
Oakland, CA
Associate Clinical Professor, Department of Pediatrics, University of California
San Francisco, CA
Chapter 35

Stella CF Blackburn MB BS MA MSc FRCP(Ed) FFPM DLSHTM Dip Pharm Med

EMEA Risk Management Coordinator, European Medicines Agency
London, United Kingdom
Chapter 21

Hege Salvesen Blix MSc Pharm

Researcher/Senior Advisor, WHO Collaborating Centre for Drug Statistics
Methodology, Department of Pharmacoepidemiology, Norwegian Institute of
Public Health
Oslo, Norway
Chapter 7

Lynne A Bosco MD MPH

Former Director, Pharmaceutical Studies, Agency for Healthcare Research and
Quality, US Department of Health and Human Services
Bethesda, MD
Chapter 27

Roselie A Bright ScD

Chief, Surveillance and Data Analysis Branch, Division of Compliance Risk
Management and Surveillance, Office of Compliance, Center for Drug Evaluation
and Research, Food and Drug Administration
Rockville, MD
Chapter 39

William H Campbell PhD

Dean Emeritus, University of North Carolina at Chapel Hill
President, Kachess Pharmaceutical Consultants LLC
Easton, WA
Chapter 24

K Arnold Chan MD ScD FISPE

Adjunct Associate Professor, Department of Epidemiology, Harvard School of
Public Health
Boston, MA
Preface, Chapters 1, 9, 42

Jennie T Chang PharmD

Office of Oncology Drug Products, Division of Drug Oncology Products, Food and Drug Administration
Silver Spring, MD
Chapter 28

Robert T Chen MD MA

HIV Vaccine Team Leader, Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention
Atlanta, GA
Chapter 31

Suzanne Cook PhD MPH

Senior Director, Worldwide Epidemiology, GlaxoSmithKline
Research Triangle Park, NC
Chapter 23

Deborah L Covington DrPH

Director, Registries & Epidemiology, Charles River Laboratories Clinical Services; Registries & Epidemiology
Wilmington, NC
Chapter 16

Thomas J Craig MD MPH

Springfield, VA
Chapter 34

Marianne C Cunningham PhD

Manager, Epidemiology, GlaxoSmithKline R&D
Worldwide Epidemiology (Neurology)
Harlow, Essex, United Kingdom
Chapter 16

Frank DeStefano MD MPH

Senior Research Epidemiologist, RTI International
Atlanta, GA
Chapter 35

Peggy Aumi Doi BS

Senior Advisor, Registries & Epidemiology, Charles River Laboratories Clinical Services; Registries & Epidemiology
Wilmington, NC
Chapter 16

Hesha J Duggirala PhD MPH

Epidemiologist, Center for Devices and Radiological Health, Food and Drug Administration
Rockville, MD
Chapter 39

I Ralph Edwards

WHO Collaborating Centre for International Drug Monitoring
Uppsala, Sweden
Chapter 10

Thomas R Einarson BScPharm MS MEd PhD

Associate Professor, Leslie Dan Faculty of Pharmacy, University of Toronto
Toronto, ON, Canada
Chapter 15

Terry S Field DSc

Associate Director, Meyers Primary Care Institute
Worcester, MA
Chapter 25

Kathleen R Frost BS

Associate Director for Regulatory Affairs, Office of Surveillance and Epidemiology,
Center for Drug Evaluation and Research, Food and Drug Administration
Silver Spring, MD
Chapter 3

Silvio Garattini MD

Director, Mario Negri Institute for Pharmacological Research
Milano, Italy
Chapter 4

Jacqueline S Gardner PhD

Professor, Department of Pharmacy, University of Washington
Seattle, WA
Chapter 22

Alicia W Gilsenan PhD MS

Director, Epidemiology, RTI Health Solutions, RTI International
Research Triangle Park, NC
Chapters 23, 24

Earl Goehring Jr BA

Managing Director, Research, The Degge Group, Ltd.
Arlington, VA
Chapter 29

Denis M Grant PhD

Professor and Chair, Department of Pharmacology, University of Toronto
Toronto, ON, Canada
Chapter 38

Kari Grave

Professor, Department of Food Safety and Infection Biology, Norwegian School of
Veterinary Science
Oslo, Norway
Chapter 40

Jeff Jianfei Guo BPharm PhD

Associate Professor, Pharmacoeconomics & Pharmacoepidemiology, College of
Pharmacy, University of Cincinnati
Cincinnati, OH
Chapter 29

Jerry H Gurwitz MD

Executive Director, Meyers Primary Care Institute
Worcester, MA
Chapter 25

Flora M Haaijer-Ruskamp PhD

Professor in Drug Utilization Studies, Department of Clinical Pharmacology,
University Medical Center/Groningen University
Groningen, Netherlands
Chapter 8

Abraham G Hartzema PharmD PhD MSPH FISPE

Professor and Eminent Scholar, Perry A Foote Chair in Health Outcomes Research
and Pharmacoeconomics, College of Pharmacy, University of Florida
Gainesville, FL
Preface, Chapters 1, 13, 42

Michael J Hensley PhD FRACP FAFPHM

Dean of Medicine, Head, School of Medicine and Public Health, University of
Newcastle, Department of Respiratory and Sleep Medicine, John Hunter Hospital
Newcastle, Australia
Chapter 33

Susan E Hilton MB BChir MA FFARCS MFPM

Associate Director, Medical Services and Clinical Risk Management, Global
Pharmacovigilance, Schering-Plough Research Institute, Schering Plough
Corporation
Springfield, NJ
Chapter 26

James R Hunter MPH RPh

Senior Program Manager, Controlled Substance Staff, Office of the Center Director,
Center for Drug Evaluation and Research, Food and Drug Administration,
Department of Health and Human Services
Rockville, MD
Chapter 3

William D Irish PhD MSc

Global Head of Biostatistics, RTI Health Solutions, RTI International
Research Triangle Park, NC
Chapter 24

Joseph D Jackson

Group Director, Outcomes Research and Policy, Research and Development,
Bristol-Myers Squibb
Princeton, NJ
Chapter 14

Judith K Jones MD PhD

President and CEO, The Degge Group, Ltd.
Arlington, VA
Chapter 29

Dianne L Kennedy RPh MPH

Program Manager, Pregnancy & Lactation Team, Center for Drug Evaluation and
Research, Food and Drug Administration
Silver Spring, MD
Chapter 16

Hilde Kruse

Department Director, Norwegian Zoonosis Center, Norwegian Veterinary Institute
Oslo, Norway
Chapter 40

Tobias Kurth MD ScD

Assistant Professor of Medicine, Harvard Medical School, Assistant Professor of
Epidemiology, Harvard School of Public Health
Divisions of Preventive Medicine and Aging, Department of Medicine, Brigham
and Women's Hospital
Boston, MA
Chapter 12

Michael A Lewis FISPE

EPES Epidemiology, Pharmacoepidemiology, and Systems Research GmbH
Berlin, Germany
Chapter 32

David E Lilienfeld MD MPH MBA MSEnglish

Foster City, CA
Chapter 41

Carolyn A McCloskey MD MPH

Medical Officer, Division of Drug Risk Evaluation, Office of Surveillance and
Epidemiology, Food and Drug Administration, CDER
Silver Spring, MD
Chapter 5

Scott A McEwen

Professor, Department of Population Medicine, Ontario Veterinary College
Guelph, ON, Canada
Chapter 40

Rosanne B McTyre PhD

Director, Biostatistics and Epidemiology, Becker & Associates Consulting, Inc.
Washington, DC
Chapter 26

Louis A Morris PhD

President, Louis A. Morris & Associates
Dix Hills, NY
Chapter 22

Trudy V Murphy MD

Associate Director for Science (Acting), Bacterial Diseases Division, National
Center for Immunization and Respiratory Diseases (proposed), Centers for
Disease Control and Prevention
Atlanta, GA
Chapter 31

Ann M Myers RPh MPH

Senior Policy Analyst, Office of the Commissioner, Food and Drug Administration
Rockville, MD
Chapter 3

Robert C Nelson PhD FISPE

President and Lead Epidemiologist, RCN Associates, Inc.
Annapolis, MD
Chapter 20

Robbin M Nighswander RPh MS

Supervisory Regulatory Health Project Manager, Division of Neurology Products,
Center for Drug Evaluation and Research, Food and Drug Administration
Silver Spring, MD
Chapter 3

Rita P Ouellet-Hellstrom PhD MPH

Epidemiologist, Division of Drug Risk Evaluation, Office of Surveillance and
Epidemiology, Food and Drug Administration, CDER
Silver Spring, MD
Chapter 5

Byung Joo Park MD PhD

Professor, Department of Preventive Medicine, College of Medicine, Seoul
National University
Seoul, Korea
Chapter 19

Neil Pearce PhD DSc

Director, Centre for Public Health Research, Massey University Wellington
Campus
Wellington, New Zealand
Chapter 33

Eleanor M Perfetto PhD MS

Senior Director, Evidence Based Strategies, Pfizer, Inc.
New York, NY
Chapter 26

Nigel SB Rawson PhD

Pharmacoepidemiologist, Medical Affairs, GlaxoSmithKline
Mississauga, ON, Canada
Adjunct Professor, Faculty of Medicine and School of Pharmacy, Memorial
University of Newfoundland
St John's, NL, Canada
Adjunct Professor, Department of Health Studies and Gerontology, University of
Waterloo
Waterloo, ON, Canada
Chapter 18

Robert F Reynolds ScD

Executive Director, Epidemiology, Pfizer, Inc.
New York, NY
Chapter 2

Leah W Ripper BA

Associate Director for Regulatory Affairs, Office of Drug Evaluation II, Center for
Drug Evaluation and Research, Food and Drug Administration
Silver Spring, MD
Chapter 3

Marit Rønning MSc Pharm

Director, WHO Collaborating Centre for Drug Statistics Methodology, Department
of Pharmacoepidemiology, Norwegian Institute of Public Health
Oslo, Norway
Chapter 7

Kenneth J. Rothman DrPH

Vice President, Epidemiology Research, RTI Health Solutions
Professor of Epidemiology and Medicine, Boston University Medical Center
Boston, MA
Foreword

Miriam E Sabin PhD

Senior Research Scientist Officer, Division of Viral Hepatitis, National Center for
HIV, Viral Hepatitis, STD and TB Prevention (proposed), Centers for Disease
Control and Prevention
Atlanta, GA
Chapter 31

Daniel J Safer MD

Associate Professor, Departments of Psychiatry and Pediatrics, Johns Hopkins
Medical Institutions
Baltimore, MD
Chapter 34

Sebastian Schneeweiss MD ScD

Associate Professor of Medicine and Epidemiology, Harvard Medical School and Harvard School of Public Health
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital
Boston, MA
Chapters 11, 13

John D Seeger PharmD DrPH

Senior Scientist and Adjunct Assistant Professor, i3 Drug Safety, Department of Epidemiology, Harvard School of Public Health
Waltham, MA
Chapter 12

Saad AW Shakir MB ChB LRCP&S FRCP FFPM FISPE MRCGP

Director, Drug Safety Research Unit
Southampton, United Kingdom
Chapter 6

Deborah Shatin

Director, Shatin Associates LLC
Plymouth, MN
Chapter 18

Henry R Shinefield MD MPH

Clinical Professor, Department of Pediatrics, Department of Dermatology, University of California School of Medicine, San Francisco
Adjunct Investigator, Division of Research, Kaiser Permanente Northern California
San Francisco, CA
Chapter 35

Paul E Stang PhD

Vice President, Cerner Galt Inc.
Blue Bell, PA
Chapter 22

Andy Stergachis PhD

Professor, Department of Epidemiology, School of Public Health and Community Medicine, and Adjunct Professor, Department of Pharmacy, Pharmaceutical Outcomes Research and Policy Program, University of Washington
Seattle, WA
Chapter 19

Miriam CJM Sturkenboom Msc PhD PharmD

Associate Professor, Pharmacoepidemiology, Departments of Epidemiology & Biostatistics and Medical Informatics, Erasmus University Medical Center
Rotterdam, Netherlands
Chapter 17

Robert Y Suruki ScD

Manager Epidemiologist, Worldwide Epidemiology Department, GlaxoSmithKline
Research Triangle Park, NC
Chapter 9

Hugh H Tilson MD DrPh

Clinical Professor of Public Health Leadership, University of North Carolina
School of Public Health
Chapel Hill, NC
Preface, Chapters 1, 16, 27, 42

Linda Tollefson

Deputy Director, Center for Veterinary Medicine, Food and Drug Administration
Rockville, MD
Chapter 40

Robert H Vander Stichele MD PhD

Senior Researcher, Department of Pharmacotherapy, Heymans Institute of
Pharmacology, Ghent University
Ghent, Belgium
Chapters 7, 8

Vera Vlahović-Palčevski MD PhD

Associate Professor, Specialist in Clinical Pharmacology, Department of Clinical
Pharmacology, University Hospital Rijeka and Department of Pharmacology,
University of Rijeka Medical School
Rijeka, Croatia
Chapter 7

I David Weiner MD

Professor of Medicine and Physiology, NF-SGVHS and Department of Medicine,
College of Medicine, University of Florida
Gainesville, FL
Chapter 37

Björn Wettermark MSc Pharm PhD

Researcher, Department of Clinical Pharmacology, Karolinska Institutet,
Karolinska University Hospital
Stockholm, Sweden
Chapter 7

Almut G Winterstein BPharm PhD

Assistant Professor, College of Pharmacy, Department of Healthcare
Administration, and College of Public Health and Health Professions, Department
of Epidemiology and Biostatistics, College of Pharmacy, University of Florida
Gainesville, FL
Chapter 37

Raymond L Woosley MD PhD

President and CEO, The Critical Path Institute

Tucson, AZ

Chapter 36

Julie Magno Zito PhD

Professor of Pharmacy and Psychiatry, Pharmaceutical Health Services Research,

School of Pharmacy, Department of Psychiatry, School of Medicine, University of

Maryland, Baltimore

Baltimore, MD

Chapter 34